Zevra therapeutics announces fda acceptance of ind application for kp1077 in narcolepsy

Zevra plans to expand kp1077 clinical program to address multiple rare sleep disorders with trials initiating in 2023

ZVRA Ratings Summary

ZVRA Quant Ranking